Premium
Osteopontin dysregulation and lytic bone lesions in multiple myeloma
Author(s) -
Robbiani Davide F.,
Colon Kaity,
Ely Sarah,
Ely Scott,
Chesi Marta,
Bergsagel P. Leif
Publication year - 2007
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.803
Subject(s) - osteopontin , lytic cycle , multiple myeloma , bone disease , cancer research , pathology , biology , immunology , microbiology and biotechnology , medicine , osteoporosis , virus
Osteopontin (OPN), a secreted phosphoprotein involved in immune regulation and bone homeostasis, is a major component of bone, the natural habitat of long‐lived plasma cells and multiple myeloma (MM). We show that only some MM cell lines and primary patient samples express OPN at high levels. High OPN expression inversely correlates with bone disease. When we subdivide MM into molecular subtypes, OPN is significantly upregulated in patients with maf translocations, particularly in the fraction lacking bone disease. OPN is produced in osteolytic lesions: we propose that MM‐derived OPN plays a critical role in bone disease by protecting bone from destruction. Copyright © 2006 John Wiley & Sons, Ltd.